# Early-stage solid tumors (breast, colon, lung, pancreatic, stomach, esophageal)

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/early-stage-solid-tumors-breast-colon-lung-pancreatic-stomach-esophage
Canonical HTML page: https://getbiobrief.com/entity/early-stage-solid-tumors-breast-colon-lung-pancreatic-stomach-esophage

## Recent coverage (1 stories)

### Lung and stomach cancer waits jump 12–14 days, raising progression risk
2026-08-18 22:36:13 · Sentiment: Negative · Impact: 6/10 · Sources: 2

Diagnosis-to-treatment intervals grew for six early-stage cancers from 2012–2023, with lung (+12 days) and stomach (+14 days) leading. For biopharma, longer real-world waits threaten neoadjuvant therapy windows and perioperative trial design.
Full story: https://getbiobrief.com/story/cancer-wait-time-clinical-implications-biopharma

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.